Shiraz Institute for Cancer Research
Iranian Journal of Immunology
1735-1383
1735-367X
18
2
2021
06
01
Immunoexpression of C4 Binding Protein in Oral Leukoplakia and Oral Squamous Cell Carcinoma
95
102
EN
Fatemeh
Mashhadi-Abbas
Oral and Maxillofacial Pathology Department, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
fmashhadiabbas@yahoo.com
Masoume
Fayazi_Boroujeni
0000-0001-5059-1003
Oral and Maxillofacial Pathology Department, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
fayazi_masoume@yahoo.com
Akram
Alizadeh
0000-0002-9956-4556
Cellular and molecular research center, basic health sciences institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
alizadehbio@gmail.com
Mahshid
Namdari
Community Oral Health Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran
namdari_mahshid@yahoo.com
Seyed Abbas
Mirzaei
0000-0003-0307-3750
School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran
dr_amirzaei@yahoo.com
10.22034/iji.2021.87031.1782
<strong>Background: </strong>The immune evasion of dysplastic cells plays an important role in suppressing the immune response and progression of malignancy. The role of the complement inhibitors in the development of oral epithelial dysplastic lesions and squamous cell carcinoma (SCC) is still unclear. <strong>Objective:</strong> This study aimed to assess the expression of C4 binding protein (C4BP) as a complement inhibitor in oral squamous cell carcinoma and leukoplakia. <strong>Methods:</strong> In this study, 94 samples were classified into four groups: leukoplakia with mild to moderate dysplasia, leukoplakia with severe dysplasia or carcinoma in situ, early invasive SCC, and invasive SCC. The expression of C4BP marker was evaluated by immunohistochemistry (IHC) and real-time PCR. The results were analyzed by the Kruskal-Wallis, Bonferroni adjusted Dunn’s multiple comparison, and one-way ANOVA tests. <strong>Results:</strong> The results of IHC revealed the expression patterns of C4BP in oral dysplasia and SCC, and indicated that the C4BP expression was not significantly different between different histopathological grades in epithelial cells and vessels (P=0.157 and P=0.123, respectively) but, it was significantly different in fibroblasts and lymphocytes (P=0.017 and P=0.043, respectively). The real-time PCR showed a significant correlation between the dysplasia grade and expression of C4BP (p <0.05). <strong>Conclusion:</strong> According to the results, C4BP is expressed in the cancerous tissue by the tumor cells and their surrounding stroma. In addition, upregulation of the C4BP gene as an inhibitor of the complement system is a possible strategy adopted by the tumor cells to evade the immune system.
Carcinoma in Situ,Complement C4b Binding Protein, Head and Neck Squamous Cell Carcinoma
https://iji.sums.ac.ir/article_47659.html
https://iji.sums.ac.ir/article_47659_7644a2c718b9ea88debd29db1c9e968f.pdf
Shiraz Institute for Cancer Research
Iranian Journal of Immunology
1735-1383
1735-367X
18
2
2021
06
01
VEGF-A, HGF and bFGF are involved in IL-17A-mediated migration and capillary-like vessel formation of vascular endothelial cells
103
110
EN
Muneo
Numasaki
0000-0001-7980-9854
Laboratory of Clinical Science and Biomedicine, Faculty of Pharmaceutical Sciences, Josai University, Sakado, Japan
mnumasaki@ns.tbgu.ac.jp
Koyu
Ito
Department of Immunology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
koyu.ito.c6@tohoku.ac.jp
10.22034/iji.2021.91214.2059
<strong>Background:</strong> Interleukin (IL)-17A possesses biological activities to promote vascular endothelial cell migration and microvessel development. <strong>Objective:</strong> To clarify which angiogenic factors are involved in IL-17A-modified angiogenesis-related functions of vascular endothelial cell migration and microtube development or not. <strong>Methods:</strong> The potential contribution of various angiogenic stimulators to in vitro angiogenic activities of IL-17A was assessed with both modified Boyden Chemotaxicell chamber assay and in vitro angiogenesis assay. <strong>Results:</strong> The addition of a neutralizing antibody (Ab) for hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF)-A to the upper and lower compartments in a modified Boyden Chemotaxicell chamber significantly attenuated human dermal microvascular endothelial cell (HMVEC) migration elicited by IL-17A. Moreover, IL-17A-induced capillary-like microvessel development in human umbilical vein endothelial cell (HUVEC) and human dermal fibroblast (HDF) co-culture system was significantly impaired by a neutralizing Ab against HGF, bFGF, VEGF-A, cysteine-x-cysteine ligand 8 (CXCL8)/IL-8 or cysteine-x-cysteine (CXC) chemokine receptor (CXCR)-2. <strong>Conclusion:</strong> Our findings demonstrate the involvement of HGF, bFGF, VEGF-A and/or CXCL8/IL-8, to various degrees, in migration and microvessel development of vascular endothelial cells mediated by IL-17A.
Angiogenesis,IL-17A,migration,tube formation,vascular endothelial cells
https://iji.sums.ac.ir/article_47664.html
https://iji.sums.ac.ir/article_47664_96c4d28d753dbafe9004bd4e564f2c73.pdf
Shiraz Institute for Cancer Research
Iranian Journal of Immunology
1735-1383
1735-367X
18
2
2021
06
01
Diospyros peregrina fruit preparation mediated immunomodulation of lymphocytes isolated from the blood of breast cancer patients
111
118
EN
Ahana
Roy
0000-0002-8287-9746
SRM Research Institute and Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India
kurinaiicandy.ahana@gmail.com
Aitijhya
Ghosh
0000-0002-9837-4208
SRM Research Institute and Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India
aitijhyaghosh@gmail.com
Kasturi
Sinha
SRM Research Institute and Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India
kasturi.sinha11@gmail.com
Basundhara
Mitra
0000-0001-5345-0740
SRM Research Institute and Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India
raiadi904@gmail.com
Sudeshna
Rakshit
0000-0002-7496-3155
SRM Research Institute and Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India
riyarakshit94@gmail.com
Melvin
George
0000-0001-7101-8513
Department of Clinical Pharmacology, SRM Medical College Hospital and Research Center, Kattankulathur, Tamil Nadu 603203, India
melvingeorge2003@gmail.com
Koustav
Sarkar
0000-0002-0696-6688
SRM Research Institute and Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India
koustavsarkar@gmail.com
10.22034/iji.2021.85430.1710
Background: Breast cancer is an uncontrolled growth of epithelial cells. The loss of BRCA1 activity due to mutation or down-regulation of gene expression promotes tumorigenesis and increases the risk of breast cancer. <br /> Objectives: Our aim was to pulsate lymphocytes of breast cancer patients and normal individuals, using Diospyros peregrina fruit preparation (DFP) to study the cancer protective immunity, and the signal transduction processes involved with it. We also investigated the role of DFP in the release of lymphocytic nitric oxide (NO), which is a key tumoricidal agent, known to regulate T-cell proliferation, cytokine production, cell signaling, and apoptosis. <br /> Methods: Using Ficoll-Hypaque gradient centrifugation, lymphocytes were isolated from the blood of 12 patients and 12 normal individuals. Cells were treated with or without DFP (2.5 µg/ml) for 48 hours. Both non-stimulated and stimulated cells were then subjected to MTT assay and NO release assay; following which qPCR was performed to estimate mRNA levels and percentage enrichment of certain genes.<br /> Results: DFP stimulates lymphocytic proliferation(p=0.0118) and release of NO(p=0.01) significantly.DFP also noticeablyenhances the expression of T helper (TH) cell 1 specific IFNG, IL12, TBX21 and signal transducer and activator of transcription 1 (STAT1) genes. DFP treatment significantly increases tumor protective immunity by decreasing the expression levels of TH2 network specific GATA3 and IL4 genes but increasing the expression levels of TH1 network specific IFNG, IL12, TBX21 and STAT1 genes. <br /> Conclusion: DFP increases the expression levels TH1 specific network genes which in turn help in evoking tumor protective immunity.
Diospyros peregrina fruit preparation (DFP),Nitric Oxide (NO),T helper (TH) cell,Breast cancer
https://iji.sums.ac.ir/article_47658.html
https://iji.sums.ac.ir/article_47658_6d3edbdd7c3f2ab2d47df3eeb3a805b8.pdf
Shiraz Institute for Cancer Research
Iranian Journal of Immunology
1735-1383
1735-367X
18
2
2021
06
01
Effect of bortezomib regimens and daratumumab monotherapy on cellular immunity in multiple myeloma patients
119
129
EN
Ashraf
Kakoo
0000-0002-7722-5289
Biology Department, College of Science, Salahaddin University, Erbil, Iraq
ashrafkako59@gmail.com
Taban
Rasheed
0000-0001-9586-7843
Biology Department, College of Science, Salahaddin University, Erbil, Iraq
taban.rasheed@su.edu.krd
Mustafa
Al-Attar
0000-0002-2106-130X
Biology Department, College of Science, Salahaddin University, Erbil, Iraq
mustafa.mustafa@su.edu.krd
10.22034/iji.2021.87547.1812
<strong>Background: </strong>Treatment with Bortezomib (a proteasome inhibitor) and Daratumumab (DARA, a monoclonal anti CD38 antibody) are effective in patients with multiple myeloma (MM). However, these drugs impair cellular immunity, which may render the patients more prone to infection. <strong>Objective</strong>: To investigate the effect of Bortezomib-based regimens and Daratumumab monotherapy on the lymphocyte subpopulations in MM patients. <strong>Methods: </strong>Peripheral blood samples were collected from 32 patients, including 29 newly diagnosed who treated with bortezomib regimens and 3 patients with relapsed and refractory MM treated with Daratumumab as monotherapy. The immunophenotypic analysis was performed by flow cytometry at baseline and during the third cycle of Bortezomib regimen and fourth week of Daratumumab treatment. <strong>Results:</strong> In the third cycle of Bortezomib, there was a significant decrease in CD3<sup>+</sup> T cells, CD<sup>+</sup>4 T cells, memory T cells, and natural killer cells (NK cells). However, CD8<sup>+</sup> T cells increased dramatically, followed by a significant reduction in the CD4/CD8 ratio. On the other hand, Daratumumab led to an increase in the T cell population after four weeks of treatment, with a significant increase in CD3<sup>+</sup> T cells as well as CD4<sup>+</sup> T cells, while NK cells were dramatically depleted in all patients. <strong>Conclusion:</strong> Bortezomib had a negative influence on subsets of T cells, while Daratumumab positively affected T cells subsets. In both treatments, NK cells decreased significantly. These results suggested that DARA is more specific to target myeloma cells than Bortezomib. Also, DARA expanded T cells especially CD3<sup>+</sup> T cells and CD4<sup>+</sup> T cells.
Bortezomib,Daratumumab (DARA),lymphocyte population,Multiple myeloma
https://iji.sums.ac.ir/article_47660.html
https://iji.sums.ac.ir/article_47660_4170419ab063f5be3b93901a6ae1bba9.pdf
Shiraz Institute for Cancer Research
Iranian Journal of Immunology
1735-1383
1735-367X
18
2
2021
06
01
IL-17 Genetic Variations Increase the Risk of Cirrhotic/Hepatocellular Carcinoma in Patients with Hepatitis B Virus Infection.
130
140
EN
Abolfazl
Gheshlaghi
Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
agheshlaghi95@gmail.com
Mohammad Reza
Haghshenas
0000-0001-8228-9888
Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
haghshenasmr@sums.ac.ir
Ali Reza
Safarpour
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
asafarpour@sums.ac.ir
Seyed Younes
Hossini
Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
hoseini.younes@gmail.com
Seyed Ali
Malekhosseini
Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
malekha@sums.ac.ir
Mohammad Reza
Fattahi
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
fattahim@sums.ac.ir
Jamal
Sarvari
0000-0002-2259-0836
Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
sarvarij@sums.ac.ir
10.22034/iji.2021.88020.1852
<strong>Background:</strong> Genetic variation in immune regulatory genes might influence the HBV infection outcome. <strong>Objective:</strong> This study aimed to determinethe association of IL-17A rs2275913 (G197A), IL-17F rs763780 (A7488G), and IL-23R rs10889677 (C2370A) gene polymorphisms, as well as the emerged haplotypes in the individual infected by HBV and to investigate their association with the infection outcome. <strong>Materials and Methods:</strong> 300 chronic HBV infections with Cirrhotic/Hepatocellular carcinoma (C/HCC), chronic active (CA), and asymptomatic carrier (AC) and 38 individuals whose infection was spontaneously cleared (SC) were enrolled. Genomic DNA was extracted, and IL-17A/F and IL-23R genotyping were performed by using the PCR-RFLP method. <strong>Results:</strong> Out of 338 subjects, 238 and 100 were respectively male and /female with a mean age of 47.61±13.41. The frequency of GA genotype (p=0.01) and A alleles (p=0.001) of IL-17A rs2275913 (G197A), as well as the frequency of AA genotype (p=0.014) and A alleles (p=0.018) of IL-17F rs763780 (A7488G) gene locus, was found to be significantly higher in the C/HCC than CA and AC groups. Furthermore, the frequency of GA and AG haplotype in CA individuals was higher than those with C/HCC and AC (p=0.003). Also, the GG haplotype was higher in AC individuals than those with C/HCC (P=0.022), and the AA haplotype was higher in C/HCC individuals than the CA patients (P=0.001). <strong>Conclusion:</strong> Our findings suggest that A allele and GA genotype at IL-17A rs2275913 (G197A), as well as A allele and AA genotype at IL-17F rs763780 (A7488G) locus, might be associated with increased risk of C/HCC among patients with hepatitis B virus infection.
Cirrhotic/Hepatocellular carcinoma,HBV,IL-17 genetic variation
https://iji.sums.ac.ir/article_47661.html
https://iji.sums.ac.ir/article_47661_a95dd4f398c818175248ccef3daa56f2.pdf
Shiraz Institute for Cancer Research
Iranian Journal of Immunology
1735-1383
1735-367X
18
2
2021
06
01
Recombinant Production and One Step Purification of IL-1Ra in Escherichia coli and Evaluation its IL-1 Antagonizing Efficacy
141
149
EN
Roya
Adelnia
Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
roya.adln@yahoo.com
Fatemeh
Shafiee
0000-0001-6484-1931
Pharmaceutical Science Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
f_shafiee@pharm.mui.ac.ir
10.22034/iji.2021.89103.1929
Background: Anakinra (Kineret®), an IL-1 receptor antagonist, is the first FDA approved biologic drug for antagonizing IL-1 effects in patients with Rheumatoid arthritis. Notably, the less expensive production of this drug might help reduce the final therapeutic costs. Objectives: This study aimed to evaluate the possibility of producing biologically active recombinant IL-1Ra by a single step purification procedure mediated by a self-cleavable intein. Methods: Soluble expression of the rIL-1Ra was performed in E. coli BL21 (DE3) in fusion to intein1 of pTWIN-1 vector and its cleavage induction using an elution buffer (pH 6.8) at room temperature. Evaluation of the antagonizing efficacy of this protein in various concentrations, was performed on A375 and HEK293 cells treated by a constant concentration of IL-1β (2ng/mL). Results: IPTG induction of E. coli BL21 (DE3) transformed with the recombinant pTWIN-1, revealed a band approximately in 45 kDa, which is related to the intein1-rIL-1Ra fusion protein in the SDS-PAGE. Moreover, protein purification was confirmed by observing a band in 18 kDa. Finally, the percentage of inhibition effects of rIL-1Ra and Kineret® against IL-1β was not statistically significant in IL-1-responsive A375 cells. The inhibition percentage was calculated as 86% in cells treated with 15µg/mL of rIL-1Ra, which it was 96% for the inhibitory effects of the standard drug. Conclusion: In this study, biologically active soluble rIL1-Ra was successfully produced with high purity through a one-step procedure. This method can reduce the cost and time of production for this protein and might be applicable for producing other biologics.
rIL-1Ra,Anakinra,Purification,IMPACT,Rheumatoid Arthritis
https://iji.sums.ac.ir/article_47663.html
https://iji.sums.ac.ir/article_47663_7cb17c589536a531871964cf32a22a4f.pdf
Shiraz Institute for Cancer Research
Iranian Journal of Immunology
1735-1383
1735-367X
18
2
2021
06
01
Camrelizumab plus zoledronic acid showed sustained efficacy in a patient with cranial and spinal metastases from lung adenocarcinoma
150
157
EN
Chu
Zhang
0000-0001-5860-8500
Department of Thoracic Surgery, Shaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, P.R.China
zhangchudoc@tom.com
Guangmao
Yu
0000-0002-1737-9243
Department of Thoracic Surgery, Shaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, P.R.China
woodbirdzhang@163.com
Miao
Zhang
0000-0001-7431-5986
Department of Thoracic Oncology, Xuzhou Central Hospital, Xuzhou, P.R.China
zhangmiaodr@163.com
Wenbin
Wu
0000-0002-8183-1687
Department of Thoracic Oncology, Xuzhou Central Hospital, Xuzhou, P.R.China
wuwb2012@163.com
10.22034/iji.2021.87760.1828
The role of anti-programmed cell death protein-1 (PD-1) antibody camrelizumab in brain metastases (BMs) from lung adenocarcinoma is uncertain. Herein, for the first time, we report the efficacy of camrelizumab in a patient with chemotherapy-refractory BMs from lung adenocarcinoma. A 49-year-old male non-smoker was admitted with cough and back pain. Primary lung adenocarcinoma with brain and spinal metastases was diagnosed. The specimen from CT-guided lung biopsy showed positive expression of PD-L1 (~20%). The BMs were enlarged after first-line intravenous pemetrexed/cisplatin and zoledronic acid; whereas second-line camrelizumab demonstrated impressive complete remission of the BMs. The intracranial progression-free survival and overall survival of the patient since immunotherapy were more than 12 months and 20 months, respectively. In addition, we searched PubMed for relevant studies from inception to May 2020, and a total of 23 reports enrolling 1187 patients also indicated the promising efficacy of immunotherapy for BMs from lung cancer. However, more and better evidence are still needed before a definite conclusion could be drawn.
programmed cell death protein-1 (PD-1),anti-PD-1 monoclonal antibody,immune checkpoint inhibitors (ICIs),Brain metastasis
https://iji.sums.ac.ir/article_47665.html
https://iji.sums.ac.ir/article_47665_95051d4b7645ea6bea3a8049ed7a3857.pdf
Shiraz Institute for Cancer Research
Iranian Journal of Immunology
1735-1383
1735-367X
18
2
2021
06
01
High level of IgG4 in a patient with Extensive pulmonary involvement
158
162
EN
Mohammad Hasan
Bemanian
0000000309984651
Department of Allergy and Clinical Immunology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
bemanian.m@iums.ac.ir
Sima
Bahrami
0000-0002-5544-6961
Department of Allergy and Clinical Immunology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
bahrami.s@iums.ac.ir
Saba
Arshi
Department of Allergy and Clinical Immunology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
arshi.s@iums.ac.ir
Afshin
Rezaeifar
Department of Allergy and Clinical Immunology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
afshinrezaeifar@gmail.com
Mohammad
Nabavi
Department of Allergy and Clinical Immunology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
nabavi.m@iums.ac.ir
Morteza
Fallahpour
0000-0002-5148-8312
Department of Allergy and Clinical Immunology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
fallahpour.m@iums.ac.ir
Sima
Shokri
0000-0002-2176-3934
Department of Allergy and Clinical Immunology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
shokri.s@iums.ac.ir
10.22034/iji.2021.88789.1907
Immunoglobulin G4-Related Disease (IgG4-RD) is a systemic fibro-inflammatory disease that has been proposed as a separate entity since thebeginning of this century. The disease is often manifested by increasedserum IgG4 levels and certain histopathological manifestations. The patientmentioned in this article is a 29-year-old man from Tajikistan, who has had achronic cough since the beginning of 2018 without a previous history of thedisease. At first, he was diagnosed with pneumonia for a long time and thenunderwent a lung biopsy due to exacerbation of symptoms and the spreadof lung lesions in radiology but no abnormalities were found in theseevaluations. The patient traveled to Iran to continue his treatment. He wasre-evaluated and then the previous samples taken from the patient's lungtissue were re-examined. There were key findings in favor of diagnosingIgG4 RD. Evaluations did not confirm the involvement of other organs. Hewas first treated with steroids and due to recurrence of symptoms, he wastreated with rituximab once which was significantly effective in improving thepatient's clinical symptoms. In general, it can be concluded that thediagnosis of IgG4-RD is very challenging and if it has not been diagnosedand treated in time, it can lead to irreversible fibrosis and permanent loss offunction of the involved organ.
fibro-inflammatory disease,Immunoglobulin G4-Related Disease,Rituximab
https://iji.sums.ac.ir/article_47662.html
https://iji.sums.ac.ir/article_47662_194ad27f3492c7a09255263eb6ae6874.pdf
Shiraz Institute for Cancer Research
Iranian Journal of Immunology
1735-1383
1735-367X
18
2
2021
06
01
Differential diagnosis from isolated lymphoid extramedullary blast crisis from secondary non-Hodgkin lymphoma in chronic myelogenous leukemia: a case report and literature review
163
169
EN
Tingting
Wang
Department of International Medical Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
tin9ting@yandex.com
Li
Fu
Department of International Medical Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
lif.fu@yandex.com
Na
Wei
Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
h0ngwei@yandex.com
Xiaoge
Zhou
Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
x1aoge@yandex.com
Xiaodan
Zheng
Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
x1aodan@yandex.com
Li
Li
Department of International Medical Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
lili_l@aliyun.com
Zhao
Wang
0000-0002-1819-8532
Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
zhao_wz@aliyun.com
10.22034/iji.2021.84496.1661
Case: Extramedullary blast crisis (EBC) is a special kind of blast crisis of chronic myelogenous leukemia (CML). It is more likely to be misdiagnosed as lymphoma when EBC cells are of lymphoid cell lineage and lymphadenopathy is the only symptom before the final diagnosis. In this study, we presented a patient with an unusual presentation of CML transformation as a rapid growth of generalized lymphadenopathy that appeared 5 months after the initial diagnosis<br />of CML. The patient underwent the left supraclavicular lymph node biopsy and repeat bone marrow aspiration. The revealed CD3+, terminal deoxynucleotidyl transferase (TdT)+, CD5+, CD23+, myeloperoxidase (MPO)-, CD20-, cyclin D1-, CD10-, which was consistent with the diagnosis of T-cell lymphoblastic lymphoma (T-LBL). Fluorescence in situ hybridization (FISH) verified the BCR-ABL rearrangement, and T-cell EBC of CML was finally diagnosed. Our report suggested that the FISH was necessary to distinguish isolated lymphoid extramedullary blast crisis from secondary NHL in CML.
chronic myelogenous leukemia,extramedullary blast crisis,secondary non-Hodgkin lymphoma
https://iji.sums.ac.ir/article_47657.html
https://iji.sums.ac.ir/article_47657_399f488c2bb3bbf7e91d813c6e1599b8.pdf